Pacific Point Podiatry, Inc | |
9500 Soquel Dr Ste A, Aptos, CA 95003-4158 | |
(831) 288-3400 | |
(831) 288-3405 |
Full Name | Pacific Point Podiatry, Inc |
---|---|
Type | Facility |
Speciality | Podiatrist - Foot & Ankle Surgery |
Location | 9500 Soquel Dr Ste A, Aptos, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558833285 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213ES0103X | Podiatrist - Foot & Ankle Surgery | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Pacific Point Podiatry, Inc 9500 Soquel Dr Ste A, Aptos, CA 95003-4158 Ph: (831) 288-3400 | Pacific Point Podiatry, Inc 9500 Soquel Dr Ste A, Aptos, CA 95003-4158 Ph: (831) 288-3400 |
News Archive
Often spending their days hunched over phones, tablets or computers and their free time at spin class or playing sports, millennials are the next generation poised to experience chronic pain. Even at their young age, millennials say acute and chronic pain are already interfering with their quality of life.
When it comes to job hiring or career advancement, a common phrase is "it's not just what you know, it's who you know," but research on weight–based bias suggests "it's how you look."
Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.
CRISPR-Cas9 is a revolutionary new gene-editing technology that has been called "molecular scissors" and has been one of the handiest tools for genetic engineers in the recent times. It makes cutting and pasting gene sequences almost as easy as it sounds. CRISPR has been hailed as a breakthrough in genetic engineering.
Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.
› Verified 1 days ago